FGEN (FibroGen, Inc.) מכפיל P/S עתידי

Demand for medical developments remains stable, yet biotech success is tied to liquidity levels. The forward P/S of FibroGen, Inc. (FGEN) reflects the asset's value dynamics, where the current status is 4.70. Delisting risks and a capital shortage following the pamrevlumab collapse are weighing on the share price, while roxadustat sales in China and the partnership with AstraZeneca create growth potential.

This indicator reflects the market valuation of the business relative to projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S ratio on the GURU.Markets platform, an investor can evaluate the extent to which the pricing power of FibroGen, Inc. (FGEN), driven by the patent protection of its drugs, justifies the company's current market capitalization in the eyes of the market.